By Matthew Holt

Yesterday XPRIZE announced the 11 finalists for the second phase of the Nokia Sensing XCHALLENGE. This is a $2.25m prize competition to advance the ability to use sensors to measure and manage health, and it’s something that we’re fascinated by at Health 2.0. You may recall that the first round’s winners were unveiled live on stage at the 2013 Health 2.0 Fall Conference by our friends at XPRIZE and Nokia.

UPDATE–The hangout is embedded above. To find out a little more, please come to a Google Hangout at 10 am Pacific/ 1pm EST Wednesday where I’ll be chatting with Dr. Erik Viirre, Medical and Technical Director of the Qualcomm Tricorder XPRIZE and the Nokia Sensing XCHALLENGE; Jonanthan Linkous, Chief Executive Officer of the American Telemedicine Association; Jon Dreyer, President of Health IT Strategic Partners; Dr. Manas Gartia from team MoboSense, a Distinguished Award winner in the Nokia Sensing XCHALLENGE Competition #1; and Dr. Marc Bailey from Nokia Technologies.

You can also see videos of the finalist teams and their breakthrough technologies can be viewed and voted on beginning today through October 30 at http://www.nokiasensingxchallengevoting.org. More on the teams below the fold:

The 11 finalist teams are:

• ARCHIMEJ TECHNOLOGY (Evry, France), a start-up led by co-founder Francisco Vega, developing technology focused on making blood analysis available remotely at an affordable price.
• Atoptix (State College, Pa.), a team of electrical engineering professors at Pennsylvania State University, led by co-founder Perry Edwards, Ph.D., focusing on mobile-based sensing of blood and tissue to assess personal health information.
• Biovotion (Zurich, Switzerland), a team led by founder and CEO Andreas Caduff, Ph.D., developing a wearable multi-sensor concept for monitoring patients with chronic conditions.
• DMI (Cambridge, Mass.), also a finalist team for the $10M Qualcomm Tricorder XPRIZE and led by Eugene Y. Chan, M.D., CEO and Head Scientist at the DNA Medicine Institute, designing a sensor that will assess hundreds clinical lab tests via a single drop of blood.
• Eigen Lifescience (Stanford, Calif.), a team of engineering faculty and students from Stanford University led by Professor Shan Wang, Ph.D., developing an ultra-portable biosensor platform that embodies a clinical lab in a mobile device.
• Endotronix Wireless Health Monitoring (Woodridge, Ill.), a team led by co-founder and CEO Harry D. Rowland, Ph.D., designing a miniature, implantable sensor with an accompanying mobile reader that helps to remotely monitor patients with chronic heart failure.
• eyeMITRA (Cambridge, Mass.), a team affiliated with the Massachusetts Institute of Technology Media Lab and led by Ramesh Raskar, Ph.D., developing a mobile phone-based imager for the early detection of diabetic retinopathy, a leading cause of adult blindness.
• Golden Gopher Magnetic Biosensing Team (Minneapolis, Minn.), a team of researchers from the University of Minnesota, Mayo Clinic and several corporate partners in the life sciences, audio electronics repair and mechanical design space. Led by Professor Jian-Ping Wang, Ph.D., they are developing a sensing device that will simultaneously detect up to 10 health indicators.
• GUES (London, England), a team of electrical engineering faculty and researchers from Imperial College and led by Professor Esther Rodriguez-Villegas, Ph.D., developing a sensor with a companion mobile app that detects sleep apnea and hypopnea.
• Hemolix (Tampa, Fla.), a team of engineers led Anna Pyayt, Ph.D., head of the Innovative Biomedical Instruments and Systems Lab at the University of South Florida, developing a mobile phone-based technology for early detection of HELLP syndrome, a dangerous pregnancy complication.
• SensoDx (Houston, Texas), a participant in the first Nokia Sensing XCHALLENGE competition (under the name Programmable Bio-Nano-Chip), led by John T. McDevitt, Ph.D., a biochemistry and engineering professor at Rice University and co-founder of SensoDx, LLC, focusing on sensor technology that can assess cardiac risk at a an early stage.